# Speaker notes / talking points

[Background · 30s] EoE is a type-2 esophageal disease with a treatment gap despite dupilumab.
[Methods · 20s] We combined bulk + single-cell omics with ESM-based triage.
[Results · 40s] The IL13/CCL26 axis dominates; CAPN14 stands out as esophagus-specific.
[Ask · 15s] We're prioritizing three targets for protein design — happy to discuss collaborations.